Tonix Pharmaceuticals Holding Corp. is a specialty pharmaceutical company focused on developing new pharmaceutical products for CNS conditions. The Company develops therapies for disorders that include fibromyalgia syndrome and post-traumatic stress disorder. Its lead product candidates include TNX-102, for the management of fibromyalgia syndrome and TNX-105 to treat symptoms of post-traumatic stress disorder. Tonix Pharmaceuticals Holding Corp. is headquartered in New York.
| Revenue (Most Recent Fiscal Year) | $10.09M |
| Net Income (Most Recent Fiscal Year) | $-130.04M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 30.65 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.50 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -1313.87% |
| Net Margin (Trailing 12 Months) | -1313.87% |
| Return on Equity (Trailing 12 Months) | -120.96% |
| Return on Assets (Trailing 12 Months) | -101.28% |
| Current Ratio (Most Recent Fiscal Quarter) | 12.31 |
| Quick Ratio (Most Recent Fiscal Quarter) | 11.64 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 0.83 |
| Book Value per Share (Most Recent Fiscal Quarter) | $24.63 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-2.84 |
| Earnings per Share (Most Recent Fiscal Year) | $-176.60 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1963.61 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 7.32M |
| Free Float | 7.32M |
| Market Capitalization | $307.78M |
| Average Volume (Last 20 Days) | 1.26M |
| Beta (Past 60 Months) | 1.63 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 0.03% |
| Percentage Held By Institutions (Latest 13F Reports) | 82.26% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |